Serious adverse events (48 to 52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (12 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
QoL · advanced gastric and oesophago‐gastric junction adenocarcinoma
1 finding from 1 review
Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to higher serious adverse events compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy probably leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy showed no clear difference in serious adverse events compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy may leads to higher tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to achieve clinical remission (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Failure to maintain clinical response · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to maintain clinical response (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to achieve endoscopic remission (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in adverse events (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in serious adverse events (5 mg/10 mg) compared with placebo (low certainty).
1 finding from 1 review